Sanofi-Aventis Completes Acquisition Of Merck Stake In Merial
18 9월 2009 - 3:09PM
Dow Jones News
French drug company Sanofi-Aventis SA (SNY) said Friday that it
has completed the acquisition of Merck & Co Inc's (MRK) 50%
interest in Merial Limited.
MAIN FACTS:
-Sanofi-Aventis acquired Merck's interest in Merial for a cash
consideration of $4 billion.
-Formed in 1997, Merial is a leading animal health company that
was a 50/50 joint venture between Merck and Sanofi-Aventis and is
now a wholly-owned subsidiary of Sanofi-Aventis.
-The acquisition of Merial is expected to be accretive to
Sanofi-Aventis' adjusted net income from the first year.
-As per the terms of the agreement signed on July 29,
Sanofi-Aventis also has an option, following the closing of the
Merck/Schering-Plough merger, to combine the
Intervet/Schering-Plough Animal Health business with Merial to form
an animal health joint venture that would be equally owned by the
new Merck and Sanofi-Aventis. If the option is exercised by
Sanofi-Aventis, the formation of the new animal health joint
venture would be subject to approval by the relevant competition
authorities.
Company Web site: www.sanofi-aventis.com
-By Paris Bureau, Dow Jones Newswires; +331-4017-1740;
alice.dore@dowjones.com